BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 8510922)

  • 1. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M; Nagano M; Shaanan B; Katzav S
    Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
    Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
    Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.
    Margolis B; Hu P; Katzav S; Li W; Oliver JM; Ullrich A; Weiss A; Schlessinger J
    Nature; 1992 Mar; 356(6364):71-4. PubMed ID: 1531699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav: Captain Hook for signal transduction?
    Katzav S
    Crit Rev Oncog; 1995; 6(2):87-97. PubMed ID: 8792085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function.
    Katzav S; Packham G; Sutherland M; Aroca P; Santos E; Cleveland JL
    Oncogene; 1995 Sep; 11(6):1079-88. PubMed ID: 7566967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of activation of the vav protooncogene.
    Coppola J; Bryant S; Koda T; Conway D; Barbacid M
    Cell Growth Differ; 1991 Feb; 2(2):95-105. PubMed ID: 2069873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
    Tian M; Martin GS
    Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR; Abe K; Karnoub AE; Der CJ
    Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vav: function and regulation in hematopoietic cell signaling.
    Bonnefoy-BĂ©rard N; Munshi A; Yron I; Wu S; Collins TL; Deckert M; Shalom-Barak T; Giampa L; Herbert E; Hernandez J; Meller N; Couture C; Altman A
    Stem Cells; 1996 May; 14(3):250-68. PubMed ID: 8724692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.
    Bustelo XR; Ledbetter JA; Barbacid M
    Nature; 1992 Mar; 356(6364):68-71. PubMed ID: 1311423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product.
    Uddin S; Yetter A; Katzav S; Hofmann C; White MF; Platanias LC
    Exp Hematol; 1996 Apr; 24(5):622-7. PubMed ID: 8605967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain.
    Zhu G; Decker SJ; Maclean D; McNamara DJ; Singh J; Sawyer TK; Saltiel AR
    Oncogene; 1994 May; 9(5):1379-85. PubMed ID: 8152798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
    Velasco JA; Avila MA; Notario V
    Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
    Rogers JA; Cheng HY; Smithgall TE
    Cell Growth Differ; 2000 Nov; 11(11):581-92. PubMed ID: 11095247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vav: a potential link between tyrosine kinases and ras-like GTPases in hematopoietic cell signaling.
    Hu P; Margolis B; Schlessinger J
    Bioessays; 1993 Mar; 15(3):179-83. PubMed ID: 8489524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroviral transduction and oncogenic selection of a cDNA encoding Dbs, a homolog of the Dbl guanine nucleotide exchange factor.
    Whitehead I; Kirk H; Kay R
    Oncogene; 1995 Feb; 10(4):713-21. PubMed ID: 7862449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes.
    Schuebel KE; Bustelo XR; Nielsen DA; Song BJ; Barbacid M; Goldman D; Lee IJ
    Oncogene; 1996 Jul; 13(2):363-71. PubMed ID: 8710375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.